JANX Stock Analysis: Buy, Sell, or Hold?
JANX - Janux Therapeutics, Inc. Common Stock
$14.91
0.57 (3.97%)
▲
5d:
+8.52%
30d:
+3.47%
90d:
+7.27%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When JANX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: JANX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: JANX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: JANX is currently trading at $14.91, which is considered extended relative to its 30-day fair value range of $13.57 to $14.48.
Technical Outlook: Technically, JANX is in a uptrend. The price is approaching resistance at $15.01. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.0% recently.
Market Sentiment: JANX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $40.56 (+172.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, JANX is in a uptrend. The price is approaching resistance at $15.01. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.0% recently.
Market Sentiment: JANX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $40.56 (+172.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$13.57 -
$14.48
Company Quality Score
67/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
68.4%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.0%)
- BULLISH: Trading 172.0% below Wall St target ($40.56)
Trading Range Analysis
30-Day Trading Range
$13.57 -
$14.48
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$12.99
Resistance Level
$15.01
Current Trend
Uptrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.38
Wall Street Target
$40.56
(+172.0%)
Revenue Growth (YoY)
2177.9%
Share & Embed Analysis
Last updated: June 23, 2026 7:53 PM ET
Data refreshes hourly during market hours. Next update: 8:53 PM
Data refreshes hourly during market hours. Next update: 8:53 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is JANX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Andrew Hollman Meyer
SELL
1879 shares
2026-01-02
Charles M Winter
SELL
2401 shares
2026-01-02
David Alan Campbell
SELL
8072 shares
2026-01-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 56 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 57 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 67 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 61 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
